Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Caribou Biosciences Inc (NQ: CRBU )

7.130 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 7.130
Bid (Size) 6.800 (100)
Ask (Size) 7.260 (2)
Prev. Close 7.130
Today's Range 7.130 - 7.130
52wk Range 4.890 - 13.19
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
3 Gene Editing Stocks to Buy Now OR You’ll Be Kicking Yourself Later
Even in a risk-off market, gene editing stocks look attractive. Here are three stocks that may be worth a closer look at this time. 
Via InvestorPlace
Caribou Biosciences to Present at 41st Annual J.P. Morgan Healthcare Conference
From Caribou Biosciences, Inc.
Via Globe NewsWire

Performance

YTD
+7.87%
+7.87%
1 Month
+7.87%
+7.87%
3 Month
-26.80%
-26.80%
6 Month
-11.10%
-11.10%
1 Year
-33.55%
-33.55%

More News

Read More
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Caribou Biosciences, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Recap: Caribou Biosciences Q2 Earnings
Via Benzinga
Caribou Biosciences Reports CB-010 ANTLER Phase 1 Trial Progress
From Caribou Biosciences, Inc.
Via Globe NewsWire
Caribou Biosciences Selects ROR1 as the Target for CB-020, an iPSC-derived Allogeneic CAR-NK Cell Therapy
From Caribou Biosciences, Inc.
Via Globe NewsWire
Precigen's Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy
Via Benzinga
Wave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That’s Heating Up
Via FinancialNewsMedia
Exposures Product Safety
Caribou Biosciences Announces the FDA Granted Regenerative Medicine Advanced Therapy (RMAT) and Fast Track Designations to CB-010, an Allogeneic Anti-CD19 CAR-T Cell Therapy
From Caribou Biosciences, Inc.
Via Globe NewsWire
Caribou Biosciences Announces FDA Clearance of IND Application for CB-011, an Allogeneic Anti-BCMA CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma
From Caribou Biosciences, Inc.
Via Globe NewsWire
Caribou Biosciences Reports Third Quarter 2022 Financial Results and Provides Business Update
From Caribou Biosciences, Inc.
Via Globe NewsWire
Caribou Biosciences to Participate in Upcoming Investor Conferences
From Caribou Biosciences, Inc.
Via Globe NewsWire
Caribou Biosciences to Present ANTLER Trial-in-Progress Poster at the 64th American Society of Hematology Annual Meeting
From Caribou Biosciences, Inc.
Via Globe NewsWire
Caribou Biosciences Presents Case Report on Long-term Follow up of First Patient Dosed in Phase 1 ANTLER Trial at the Lymphoma, Leukemia, & Myeloma Congress 2022
From Caribou Biosciences, Inc.
Via Globe NewsWire
Valneva, Take-Two Interactive And Some Other Big Stocks Moving Lower In Today's Pre-Market Session
Via Benzinga
Why bluebird bio Is Trading Higher By Around 19%; Here Are 31 Stocks Moving Premarket
Via Benzinga
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Via Benzinga
Caribou's Blood Cancer Candidate Shows Response Rates Better Than Novartis,' This Analyst Writes
Via Benzinga
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
93 Biggest Movers From Yesterday
Via Benzinga
Analysts Remain Bullish Despite Caribou's Allogeneic CAR-T Hit By Durability
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
70 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.